F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of pain, cancer, inflammatory bowel disease, endometriosis, asthma, mental diseases and neurological and renal disorders.